Klimm, Beate, Franklin, Jeremy ORCID: 0000-0003-1536-0925, Stein, Harald, Eichenauer, Dennis A., Haverkamp, Heinz ORCID: 0000-0001-6895-4132, Diehl, Volker, Fuchs, Michael, Borchmann, Peter and Engert, Andreas (2011). Lymphocyte-Depleted Classical Hodgkin's Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group. J. Clin. Oncol., 29 (29). S. 3914 - 3921. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Full text not available from this repository.

Abstract

Purpose To investigate the clinical characteristics and treatment outcome of patients with lymphocyte-depleted classical Hodgkin's lymphoma (LDCHL) compared with other histologic subtypes of Hodgkin's lymphoma (HL). Patients and Methods From a total of 12,155 evaluable patients with biopsy-proven HL treated within the German Hodgkin Study Group trials HD4 to HD15, 10,019 patients underwent central expert pathology review. Eighty-four patients with LDCHL (< 1%) were identified and confirmed. The median follow-up time was 67 months. Results Patients with LDCHL, compared with patients with other histologic subtypes, presented more often with advanced disease (74% v 42%, respectively; P < .001) and B symptoms (76% v 41%, respectively; P < .001). Other risk factors were also more frequent in patients with LDCHL. Complete remission or unconfirmed complete remission was achieved in 82% of patients with LDCHL compared with 93% of patients with other HL subtypes (P < .001), and more patients with LDCHL had progressive disease. At 5 years, progression-free survival (PFS) and overall survival (OS) were significantly lower in patients with LDCHL compared with patients with other HL subtypes (PFS, 71% v 85%, respectively; P < .001; OS, 83% v 92%, respectively; P = .0018). However, when analyzing the subgroup of patients who underwent treatment with intensified or dose-dense bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone, patients with LDCHL (n = 39) had similar outcomes when compared with patients with other subtypes of HL (n = 3,564; P = .61). Conclusion LDCHL has a different pattern from other HL subtypes with more clinical risk factors at initial diagnosis and significantly poorer prognosis. Patients with LDCHL should be treated with modern dose-intense treatment strategies.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Klimm, BeateUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Franklin, JeremyUNSPECIFIEDorcid.org/0000-0003-1536-0925UNSPECIFIED
Stein, HaraldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Eichenauer, Dennis A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Haverkamp, HeinzUNSPECIFIEDorcid.org/0000-0001-6895-4132UNSPECIFIED
Diehl, VolkerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fuchs, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Borchmann, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Engert, AndreasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-487381
DOI: 10.1200/JCO.2011.36.4703
Journal or Publication Title: J. Clin. Oncol.
Volume: 29
Number: 29
Page Range: S. 3914 - 3921
Date: 2011
Publisher: AMER SOC CLINICAL ONCOLOGY
Place of Publication: ALEXANDRIA
ISSN: 1527-7755
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
EXTENDED-FIELD RADIOTHERAPY; STUDY-GROUP GHSG; PROGNOSTIC-FACTORS; RANDOMIZED-TRIAL; COPP-ABVD; DISEASE; CHEMOTHERAPY; COPP/ABV/IMEP; BLEOMYCIN; SUPERIORMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/48738

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item